# Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum
Canonical URL: https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-to-participate-in-fireside-chat-at-the-stifel-2025-virtual-49c0bb84
Ticker: CGEM
Company: Cullinan Therapeutics, Inc.
Source: Cullinan Therapeutics, Inc.
Published: 2025-09-12 11:00 EST
## Summary

Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on...

## Article Body
Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on Tuesday, September 16, 2025, at 9:30 a.m. ET.

A webcast of the fireside chat will be available under the Events and Presentations section of the Company’s investor relations website at https://investors.cullinantherapeutics.com/events .

About Cullinan Therapeutics

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients. Cullinan has strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both autoimmune diseases and cancer. Cullinan’s portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of autoimmune and cancer indications. We push conventional boundaries from candidate selection to differentiated therapeutic, applying rigorous go/no go criteria at each stage of development to fast-track only the most promising molecules to the clinic and, ultimately, commercialization. With deep scientific expertise, our teams exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients. Learn more about Cullinan at https://cullinantherapeutics.com/ , and follow us on LinkedIn and X .

Contacts:

Investor Relations Nick Smith +1 401.241.3516 nsmith@cullinantx.com

Media Rose Weldon +1 215.801.7644 rweldon@cullinantx.com
## Recent Company News
- 2026-07-28 11:00 EST — [Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML](https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-announces-positive-end-of-phase-1-meeting-with-fda-for-cln-68006175) — Source: Cullinan Therapeutics, Inc.
- 2026-06-10 11:30 EST — [Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases](https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-shares-new-clinical-data-across-its-portfolio-of-t-cell-en-1824446e) — Source: Cullinan Therapeutics, Inc.
- 2026-06-06 09:15 EST — [Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress](https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-presents-initial-clinical-data-for-cln-978-a-cd19xcd3-t-ce-5c413068) — Source: Cullinan Therapeutics, Inc.
- 2026-05-26 11:00 EST — [Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager](https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-to-host-immunology-day-to-showcase-promising-initial-clini-cc2e30f1) — Source: Cullinan Therapeutics, Inc.
- 2026-05-19 11:00 EST — [Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia](https://biopharmsignal.com/news/CGEM/cullinan-therapeutics-receives-fda-orphan-drug-designation-for-cln-049-a-novel-f-c84381bb) — Source: Cullinan Therapeutics, Inc.
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)